Trial · NCT01209234
Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
NCT01209234, Not applicable, Completed, University of California, Irvine; results first posted 2020-09-17
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance. Trials, record NCT01209234. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01209234
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
- NCT number
- NCT01209234
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 2,140 participants, actual
- Lead sponsor
- University of California, Irvine
- Conditions
- Methicillin-resistant Staphylococcus Aureus
- Interventions
- Standard-of-Care Education, MRSA Decolonization
- First posted
- 2010-09-27
- Last updated
- 2025-11-21
- Results first posted
- 2020-09-17
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to MRSA Infection | 1 year | Time in days to MRSA inpatient or outpatient infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year post discharge) |
| Secondary | Time to All-cause Infection (Steering Committee Modified Oct 2011) | 1 year | Time in days to all-cause infection (analyzed with the use of unadjusted Cox proportional-hazard models to identify time to infection; the results we are reporting are number of participants who had an infection event at one year) |
| Other | Number of MRSA Infections | 1 year | Event count of outpatient and inpatient MRSA infections occurring after enrollment |
| Other | Rehospitalization Due to MRSA Infection | 1 year | Number of participants experiencing rehospitalization due to MRSA infection (first only) |
| Other | Cost and Cost Savings Associated With Post-discharge MRSA Decolonization | 1 year | Medical and non-medical costs of MRSA infection within the 1 year follow up period |
| Other | Number of All-cause Infections | 1 year | Event count of all-cause infections occurring after enrollment |
Source ClinicalTrials.gov
Outcomes6
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time to MRSA Infection | 1 year | Outcomes were analyzed according to the as-treated adherence strata (fully adherent, partially adherent, and nonadherent participant-time) | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to All-cause Infection (Steering Committee Modified Oct 2011) | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Number of MRSA Infections | 1 year | MRSA Infection Events | NUMBER | |
| OTHER_PRE_SPECIFIED | Rehospitalization Due to MRSA Infection | 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| OTHER_PRE_SPECIFIED | Cost and Cost Savings Associated With Post-discharge MRSA Decolonization | 1 year | |||
| OTHER_PRE_SPECIFIED | Number of All-cause Infections | 1 year | All-cause infection events | NUMBER |
Source ClinicalTrials.gov
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to MRSA Infection | MRSA Decolonization | MRSA Infection defined by CDC Criteria | 67 | Participants | |
| Time to MRSA Infection | Education Arm | MRSA Infection defined by CDC Criteria | 98 | Participants | |
| Time to MRSA Infection | MRSA Decolonization | MRSA Infection defined by Clinical Criteria | 68 | Participants | |
| Time to MRSA Infection | Education Arm | MRSA Infection defined by Clinical Criteria | 98 | Participants | |
| Time to All-cause Infection (Steering Committee Modified Oct 2011) | MRSA Decolonization | All-Cause Infection defined by CDC Criteria | 207 | Participants | |
| Time to All-cause Infection (Steering Committee Modified Oct 2011) | Education Arm | All-Cause Infection defined by CDC Criteria | 252 | Participants | |
| Time to All-cause Infection (Steering Committee Modified Oct 2011) | MRSA Decolonization | All-Cause Infection defined by Clinical Criteria | 246 | Participants | |
| Time to All-cause Infection (Steering Committee Modified Oct 2011) | Education Arm | All-Cause Infection defined by Clinical Criteria | 298 | Participants | |
| Number of MRSA Infections | MRSA Decolonization | 67 | MRSA Infection Events | ||
| Number of MRSA Infections | Education Arm | 98 | MRSA Infection Events |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | MRSA Decolonization | 1,070 | |
| Overall Study | STARTED | Education Arm | 1,070 | |
| Overall Study | COMPLETED | MRSA Decolonization | 1,058 | |
| Overall Study | COMPLETED | Education Arm | 1,063 | |
| Overall Study | NOT COMPLETED | MRSA Decolonization | 12 | |
| Overall Study | NOT COMPLETED | Education Arm | 7 |
Source ClinicalTrials.gov
Adverse events58
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Nasal Mupirocin (2%) | Respiratory, thoracic and mediastinal disorders | MRSA Decolonization | 5 | 1,058 | 5 |
| other | Nasal Mupirocin (2%) | Respiratory, thoracic and mediastinal disorders | Education Arm | 0 | 1,063 | 0 |
| other | Nasal Mupirocin (2%) | General disorders | MRSA Decolonization | 1 | 1,058 | 1 |
| other | Nasal Mupirocin (2%) | General disorders | Education Arm | 0 | 1,063 | 0 |
| other | Nasal Mupirocin (2%) | General disorders | MRSA Decolonization | 1 | 1,058 | 1 |
| other | Nasal Mupirocin (2%) | General disorders | Education Arm | 0 | 1,063 | 0 |
| other | Nasal Mupirocin (2%) | General disorders | MRSA Decolonization | 1 | 1,058 | 1 |
| other | Nasal Mupirocin (2%) | General disorders | Education Arm | 0 | 1,063 | 0 |
| other | Nasal Mupirocin (2%) | General disorders | MRSA Decolonization | 1 | 1,058 | 1 |
| other | Nasal Mupirocin (2%) | General disorders | Education Arm | 0 | 1,063 | 0 |
1 to 10 of 58Source ClinicalTrials.gov
See all 58 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | MRSA Decolonization | 0 | 1,058 |
| Total, all-cause mortality | Education Arm | 0 | 1,063 |
| Total, other adverse events | MRSA Decolonization | 48 | 1,058 |
| Total, other adverse events | Education Arm | 0 | 1,063 |
| Total, serious adverse events | MRSA Decolonization | 0 | 1,058 |
| Total, serious adverse events | Education Arm | 0 | 1,063 |
Source ClinicalTrials.gov
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| MRSA Decolonization vs Education Arm: Rehospitalization Due to MRSA Infection | Trial comparisons |
| MRSA Decolonization vs Education Arm: deaths from any cause | Trial comparisons |
| MRSA Decolonization vs Education Arm: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01209234
GET https://conductscience.org/api/trials/v1/NCT01209234/events?page=2